Marks JD - Search Results

1

Development of ligand-targeted liposomes for cancer therapy.

Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, Benz CC, Marks JD, Drummond DC. Noble CO, et al. Among authors: marks jd. Expert Opin Ther Targets. 2004 Aug;8(4):335-53. doi: 10.1517/14728222.8.4.335. Expert Opin Ther Targets. 2004. PMID: 15268628 Review.

2

Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function.

Neve RM, Nielsen UB, Kirpotin DB, Poul MA, Marks JD, Benz CC. Neve RM, et al. Among authors: marks jd. Biochem Biophys Res Commun. 2001 Jan 12;280(1):274-9. doi: 10.1006/bbrc.2000.4104. Biochem Biophys Res Commun. 2001. PMID: 11162510

3

Tumor targeting using anti-her2 immunoliposomes.

Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC. Park JW, et al. Among authors: marks jd. J Control Release. 2001 Jul 6;74(1-3):95-113. doi: 10.1016/s0168-3659(01)00315-7. J Control Release. 2001. PMID: 11489487

4

Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.

Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC. Park JW, et al. Among authors: marks jd. Clin Cancer Res. 2002 Apr;8(4):1172-81. Clin Cancer Res. 2002. PMID: 11948130

5

Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis.

Nielsen UB, Kirpotin DB, Pickering EM, Hong K, Park JW, Refaat Shalaby M, Shao Y, Benz CC, Marks JD. Nielsen UB, et al. Among authors: marks jd. Biochim Biophys Acta. 2002 Aug 19;1591(1-3):109-118. doi: 10.1016/s0167-4889(02)00256-2. Biochim Biophys Acta. 2002. PMID: 12183061 Free article.

6

Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.

Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW. Mamot C, et al. Among authors: marks jd. Cancer Res. 2003 Jun 15;63(12):3154-61. Cancer Res. 2003. PMID: 12810643

7

Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells.

Liu B, Conrad F, Cooperberg MR, Kirpotin DB, Marks JD. Liu B, et al. Among authors: marks jd. Cancer Res. 2004 Jan 15;64(2):704-10. doi: 10.1158/0008-5472.can-03-2732. Cancer Res. 2004. PMID: 14744788

8

Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification.

Nellis DF, Ekstrom DL, Kirpotin DB, Zhu J, Andersson R, Broadt TL, Ouellette TF, Perkins SC, Roach JM, Drummond DC, Hong K, Marks JD, Park JW, Giardina SL. Nellis DF, et al. Among authors: marks jd. Biotechnol Prog. 2005 Jan-Feb;21(1):205-20. doi: 10.1021/bp049840y. Biotechnol Prog. 2005. PMID: 15903260

9

Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis.

Nellis DF, Giardina SL, Janini GM, Shenoy SR, Marks JD, Tsai R, Drummond DC, Hong K, Park JW, Ouellette TF, Perkins SC, Kirpotin DB. Nellis DF, et al. Among authors: marks jd. Biotechnol Prog. 2005 Jan-Feb;21(1):221-32. doi: 10.1021/bp049839z. Biotechnol Prog. 2005. PMID: 15903261

10

Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery.

Hayes ME, Drummond DC, Kirpotin DB, Zheng WW, Noble CO, Park JW, Marks JD, Benz CC, Hong K. Hayes ME, et al. Among authors: marks jd. Gene Ther. 2006 Apr;13(7):646-51. doi: 10.1038/sj.gt.3302699. Gene Ther. 2006. PMID: 16341056

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

296 results

Search Page